Commonly Used Quality of Life and Symptom Measurement Scales

Publication
Article
OncologyONCOLOGY Vol 16 No 9
Volume 16
Issue 9

On the following pages are examples of commonly used scales for evaluating quality of life and symptoms associated with anemia in patients with cancer. Please note that some of the scales are copyrighted (and marked as such herein) and may not be reproduced in anyway without the express written consent of the copyright holders.

On the following pages are examples of commonly used scales for evaluating quality of life and symptoms associated with anemia in patients with cancer. Please note that some of the scales are copyrighted (and marked as such herein) and may not be reproduced in anyway without the express written consent of the copyright holders.

Fatigue Symptoms Inventoty (FSI)
(Paul Jacobsen)

Multidimentional Fatigue Inventory (MFI-20)
(Ellen Smets and colleagues)

Brief Fatigue Inventory
(Charles Cleeland and colleagues)

Piper Fatigue Scale (PFS)
(Barbara Piper and colleagues)

FACIT-Fatigue Scale (Version 4)
(David Cella)

FACT-Anemia (FACT-An)
(David Cella)

EORTC: QLC-C30 (Version 3)
(Karen West)

Rotterdam Symprom Checklist
(Johanna de Haes and colleagues)

SWOG Quality of Life Questionaire
(Carol Moinpour and colleagues)

Quality of Life Index Cancer Version-III
(Carol Ferrans and Marjorie Powers)

CAncer Rehabilitation Evaluation System (CARES)
(Anne Coscarelli and Richard Heinrich)

Functional Living Index: Cancer (FLIC)
(Harvey Schipper abd Charles Olweny)

Quality of Life Index
(Cary Presant and colleagues)

L.A.S.A Scale and Quality of Lide Index Form: Form Q1
(Dianne Lindsay)

M.D. Ansderson Symptom Inventory (MDASI)
(Charles Cleeland)

McMaster Health Index Questionnaire
(Larry Chambers)

RAND 36-Item Health Survey 1.0 Questionnaire
(Judy Lewis)

 

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content